PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
PARPs in Practice in mCRPC: A Look at the Latest Data
Visit https://www.peervoice.com/CVG860 to view the entire programme with slides. After completing “PARPs in Practice in mCRPC: A Look at the Latest Data”, participants will be able to: Describe the most recent clinical data for poly ADP ribose polymerase (PARP) inhibitors for metastatic castration-resistant prostate cancer (mCRPC), including combination regimens; Outline patient-centred strategies to improve quality of life, adherence, and other outcomes in patients with mCRPC; and Identify strategies for optimal monitoring and management of adverse events associated with PARP inhibitors.